GlassScriptPhysician profile
Raheem Lalani
NPI 1376169185
$2,114.53
in general payments reported to CMS, 2019-2025
25 companies · $843 in 2025
The $843 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $264 · 2024: $1,008 · 2025: $843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,114.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $428.45 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $387.28 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $206.23 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $176.17 | 2023-2025 | |
| Exact Sciences Corporation | $161.15 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $155.90 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Dexcom, INC. | $119.12 | 2024-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $92.98 | 2023-2025 | Spravato |
| Idorsia Pharmaceuticals US INC | $50.92 | 2023-2024 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.82 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $27.09 | 2025 | Givlaari |
| Inari Medical, INC. | $27.01 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Madrigal Pharmaceuticals | $23.41 | 2025 | Rezdiffra |
| Abbvie INC. | $22.83 | 2024 | |
| Philips North America LLC | $22.65 | 2024 | (Ck7) Extended Holter |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $22.06 | 2024 | Fluad, Flucelvax |
| Renalytix Ai, INC. | $19.99 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Inspire Medical Systems, INC. | $19.69 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $18.66 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Edwards Lifesciences Corporation | $17.99 | 2024 | Sapien 3 Ultra Resilia |
| Axsome Therapeutics, INC. | $17.61 | 2025 | Auvelity |
| Itamar Medical INC | $17.43 | 2024 | Watchpatone |
| Astellas Pharma US INC | $15.24 | 2025 | Veozah |
| Kyowa Kirin, INC. | $14.75 | 2025 | |
| Amgen INC. | $14.10 | 2025 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raheem Lalani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.